Efficacy of Ayurveda Treatment Protocol Compared to Vonoprazan in Patients with Functional Dyspepsia (Amlapitta): Research Protocol for a Randomised Controlled Trial

Introduction: Functional Dyspepsia (FD) is a common gastrointestinal disorder characterised by postprandial fullness, early satiety, and epigastric pain.Conventional management typically focuses on acid suppression and symptom control through pharmacotherapy. While this approach may provide temporary relief, concerns about recurrence and long-term safety highlight the need for alternative and complementary therapeutic strategies for effective long-term management of FD. Need of the study: This study evaluates a predefined, RAND/UCLA consensus-developed, standardised doshabased Ayurveda treatment protocol against standard pharmacotherapy. Vonoprazan is selected as the comparator, as current clinical guidelines recommend acid-suppressive therapy as the first-line pharmacological approach for FD, and vonoprazan, a potent potassium-competitive acid blocker, represents a contemporary option. Aim: To assess the efficacy and safety of a dosha-based Ayurveda protocol compared with vonoprazan in patients with FD. Materials and Methods: This open-label, randomised, parallel-group trial will be conducted at KAHER Shri BMK Ayurveda Mahavidyalaya and KLE Ayurveda Hospital, Belagavi, Karnataka, from January 2026 to May 2027. Sixty participants meeting ROME-IV diagnostic criteria for FD will be included. Participants will receive either the predefined dosha-based Ayurveda protocol or vonoprazan therapy for 28 days, with follow-up until day 56. Primary and secondary outcomes will evaluate dyspepsia severity, symptom burden, Quality of Life (QoL), and safety using validated tools. Depending on distribution, intergroup comparisons will be performed using the independent t-test or Mann-Whitney U test for continuous variables, and Chi-square or Fisher’s exact test for categorical variables. Intragroup comparisons will use the paired t-test or Wilcoxon signedrank test. A p-value <0.05 will be considered statistically significant.

Authors

Publication Details

Journal
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
Published
2026-11-18
DOI
https://doi.org/10.7860/jcdr/2026/87575.24816
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of Ayurveda Treatment Protocol Compared to Vonoprazan in Patients with Functional Dyspepsia (Amlapitta): Research Protocol for a Randomised Controlled Trial

Bawadkar Prasad, Vrushali Zanzad, Rajjimunisa Begam Shaik, Sunil Kumar
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
Gastrointestinal motility and disorders
article

Efficacy of Ayurveda Treatment Protocol Compared to Vonoprazan in Patients with Functional Dyspepsia (Amlapitta): Research Protocol for a Randomised Controlled Trial

Bawadkar Prasad, Vrushali Zanzad, Rajjimunisa Begam Shaik, Sunil Kumar
article en

Abstract

Introduction: Functional Dyspepsia (FD) is a common gastrointestinal disorder characterised by postprandial fullness, early satiety, and epigastric pain.Conventional management typically focuses on acid suppression and symptom control through pharmacotherapy. While this approach may provide temporary relief, concerns about recurrence and long-term safety highlight the need for alternative and complementary therapeutic strategies for effective long-term management of FD. Need of the study: This study evaluates a predefined, RAND/UCLA consensus-developed, standardised doshabased Ayurveda treatment protocol against standard pharmacotherapy. Vonoprazan is selected as the comparator, as current clinical guidelines recommend acid-suppressive therapy as the first-line pharmacological approach for FD, and vonoprazan, a potent potassium-competitive acid blocker, represents a contemporary option. Aim: To assess the efficacy and safety of a dosha-based Ayurveda protocol compared with vonoprazan in patients with FD. Materials and Methods: This open-label, randomised, parallel-group trial will be conducted at KAHER Shri BMK Ayurveda Mahavidyalaya and KLE Ayurveda Hospital, Belagavi, Karnataka, from January 2026 to May 2027. Sixty participants meeting ROME-IV diagnostic criteria for FD will be included. Participants will receive either the predefined dosha-based Ayurveda protocol or vonoprazan therapy for 28 days, with follow-up until day 56. Primary and secondary outcomes will evaluate dyspepsia severity, symptom burden, Quality of Life (QoL), and safety using validated tools. Depending on distribution, intergroup comparisons will be performed using the independent t-test or Mann-Whitney U test for continuous variables, and Chi-square or Fisher’s exact test for categorical variables. Intragroup comparisons will use the paired t-test or Wilcoxon signedrank test. A p-value <0.05 will be considered statistically significant.

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon